BRIEF—Cedrus and Xiuzheng seek 'win-win' partnership

Swiss financial group Cedrus is to collaborate with Chinese pharma giant Xiuzheng Pharmaceutical to identify investment opportunities in China.

Established in 1995, Xiuzheng generates around $10 billion in annual revenues, focusing on the R&D, production and marketing of branded medicines, among other things.

In a statement, Cedrus said it was looking to “invest in the world's leading innovators in the sector and become their trusted partner in their expansion."

Leveraging its expertise in the sector, Cedrus said it would also act as a “holistic enabler and connector between Xiuzheng and overseas technologies and products,” helping the firm “establish itself on a global-scale.”

Chairman Rani Jarkas described the deal as a “momentous win-win situation.”